美国Mirus Bio  www.mirusbio.com
Mirus Bio公司是RNA干扰和基因治疗领域的领先者。该公司的Dynamic PolyConjugates技术改良后能成为siRNA疗法的平台。在基因治疗方面，该公司通过专利的Pathway IV hydro- dynamic delivery平台开发了全新的人类疗法。主要项目是与Transgene S.A.合作开发的肌肉萎缩症治疗。另外，Mirus还推出了最先进的DNA和siRNA转染、标记产品。

2008年罗氏以1.25亿美元收购RNAi和基因治疗公司Mirus

Corporate Overview
Mirus Bio LLC is a life science company focused on discovering, developing and commercializing innovative nucleic acid based technologies and products.
Mirus R&D uniquely integrates nucleic acid delivery and chemistry, a core competency which is unmatched in the industry. This serves as the foundation for its novel research reagents.
RESEARCH REAGENTS
Mirus is a recognized leader in developing innovative nucleic acid research reagents, distinguished by its many accomplishments:
First to develop an siRNA transfection reagent (2001) 
Pioneered development of high efficiency/low toxicity transfection formulations 
First to market a single step nucleic acid labeling technology 
Unique technology to label native, biologically relevant short RNA species such as microRNA 
Mirus’ TransIT® Reagents are unique lipid and polymer formulations that achieve superior delivery efficiency of pDNA and siRNA with minimal cytotoxic effects. They have been optimized for in vitro delivery in a variety of mammalian cells as well as for in vivo delivery in small animals. The Ingenio™ Electroporation Solution allows researchers to deliver nucleic acids to cells that are resistant to transfections.
The company’s Label IT® Kits employ proprietary chemistry to covalently attach labeling molecules to DNA and RNA. This simple one-step process is faster and more robust than traditional multi-step enzymatic labeling, and can be used for intracellular tracking, chromosome analysis, and microarray labeling.
CORPORATE HISTORY
Internationally recognized gene therapy specialist, Jon Wolff, along with his colleagues James Hagstrom and Vladimir Budker founded the company in 1995, based on research they performed at the University of Wisconsin-Madison.
Mirus was founded on the principle that non-viral (i.e. plasmid DNA based) methods offer distinct advantages over viral methods of gene transfer. Following this path, Mirus has pioneered the development of a wide range of non-viral delivery technologies using proteins, polymers, and lipids in conjunction with novel chemistries that provide unique nucleic acid delivery capabilities.
MARKETED RESEARCH PRODUCTS
TransIT® Transfection Reagents
- pDNA and DNA vectors
- siRNA, mRNA and viral RNA 
Label IT® Labeling Reagents
- DNA & RNA, including miRNA 
Ingenio™ Electroporation Solutions
- DNA 
CORPORATE INFORMATION
FOCUS
Specialists in nucleic acid chemistry and delivery
TECHNOLOGY PORTFOLIO
Synthetic siRNA Delivery
shRNA Expression Vector Delivery
Transfection Reagents
Labeling Reagents
Electroporation Reagents
OWNERSHIP
Privately held